Work

Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)